| | |
| Clinical data | |
|---|---|
| Trade names | Naxcel |
| AHFS/Drugs.com | International Drug Names |
| ATCvet code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H17N5O7S3 |
| Molar mass | 523.55 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Ceftiofur is an antibiotic of the cephalosporin type (third generation), licensed for use in veterinary medicine. It was first described in 1987. [3] It is marketed by pharmaceutical company Zoetis as Excenel, [4] Naxcel, and Excede and is also the active ingredient in that company's Spectramast LC (lactating cow formulation) and Spectramast DC (dry cow formulation) product.[ citation needed ]
It is resistant to the antibiotic resistance enzyme beta-lactamase, and has activity against both Gram-positive and Gram-negative bacteria. Escherichia coli strains resistant to ceftiofur have been reported. [5]
The metabolite desfuroylceftiofur also has antibiotic activity. [6] The two compounds are measured together to measure for antibiotic activity in milk (alongside other antibiotics). [7]